(Q37921761)

25 August 2017

What happens when natalizumab therapy is stopped? (English)

1 reference

25 August 2017

Stephen M Schaaf

1

1 reference

25 August 2017

David Pitt

series ordinal

2

1 reference

25 August 2017

Michael K Racke

series ordinal

3

1 reference

25 August 2017

1 September 2011

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

25 August 2017

1 reference

25 August 2017

11

1 reference

25 August 2017

9

1 reference

25 August 2017

1247-1250

1 reference

Multiple sclerosis--the plaque and its pathogenesis

25 August 2017

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.109

Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.109

Immune surveillance in multiple sclerosis patients treated with natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.109

Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.109

A controlled trial of natalizumab for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.109

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.109

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.109

Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.109

Anti-JC virus antibodies: implications for PML risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.109

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.109

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.109

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.109

21 January 2018

Identifiers

DOI

10.1586/ERN.11.109

1 reference

release_jf3bth4v3rgibaeh7l7rydbkry

25 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jf3bth4v3rgibaeh7l7rydbkry

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference